DSIT: Why Growth Got Stuck in Contract Assets and Guarantee Capacity
2025 was a real growth year, but note 6 shows that execution ran ahead of billing by about $12.2 million and pushed DSIT from customer-funded execution toward self-funded projects. The March 2026 IPO eased the liquidity pressure, but it did not remove the next bottleneck: the bank-guarantee capacity needed to keep growing.
The main article already established that 2025 was a real growth year but a weak cash year. This follow-up isolates the mechanism that broke cash conversion: DSIT moved from a model where the customer funded a meaningful part of execution through advances and early billing to one where the company was working ahead of the invoice. In a business that also has to post advance-payment and performance guarantees, that pressure does not stop at the cash balance. It spills directly into banking capacity.
Three numbers tell the whole story. Contract assets rose to $17.5 million from $4.7 million. The net contract position moved from negative $7.3 million at the end of 2024 to positive $4.9 million at the end of 2025. The guarantee stock rose to about NIS 118.3 million, while the committed NIS 76 million guarantee line was almost fully used. This is no longer a minor timing gap. It is a change in how growth is being funded.
Where 2025 Turned
Note 6 shows the shift very clearly. In 2024, billings issued under construction contracts reached $24.129 million against $18.724 million of recognized revenue. In other words, customers were ahead of revenue recognition by about $5.4 million. In 2025 the direction reversed: recognized revenue rose to $35.067 million, but billings issued were only $22.909 million. The gap was about $12.2 million in favor of work already recognized but not yet billed.
That is the direct reason contract assets jumped so sharply, and it is also why contract liabilities did almost nothing to offset the move. They rose only to $12.617 million from $12.027 million. Customer funding did not disappear, but it stopped being the dominant force in the model.
The important nuance is that the jump was highly concentrated. The director report states explicitly that most of the increase in contract assets came from two maritime customers: customer A at about $3.677 million and customer B at about $8.372 million. Together that is $12.049 million, almost the entire annual increase in the account. This was not broad deterioration across the company. It was concentrated execution pressure inside the maritime projects that drove growth.
The company also explains the underlying mechanism. At the start of a project, receipts often exceed recognized revenue and therefore create contract liabilities. As the project progresses, those balances shrink and can even turn into contract assets. The analytical implication is straightforward. 2025 was not only a backlog year or a revenue year. It was the year in which part of the project base moved into the phase where DSIT was funding more of the work until the billing point.
Why Cash Flow Broke
The cash-flow statement leaves little room for interpretation. The company ended 2025 with $5.609 million of net income, but operating cash flow of negative $6.876 million. That was not caused by a broad operational collapse. It was caused by working capital consuming the year.
The single largest line was a $15.174 million increase in receivables, other receivables, and contract assets. On the other side, the increase in suppliers, contract liabilities, accrued expenses, and other liabilities added only $2.747 million. So even after profit, depreciation, deferred taxes, interest, and other non-cash items, cash was left behind.
What matters here is that the company did not stumble because sales were weak. Quite the opposite. It stumbled because the pace of execution and revenue recognition was much faster than the pace at which customers could be billed. That is a very different kind of problem. It is less dramatic than weak demand, but it can be just as restrictive because it transfers the funding burden from the customer to the supplier.
That is also why the line saying the company has no outstanding bank loans can mislead. A business can have no classic financial debt and still face a growing need to self-fund execution. In 2025, that is exactly what DSIT looked like.
Where Guarantees Enter The Picture
This is where section 14 becomes critical. The company says it uses guarantee lines to issue bank guarantees to customers, both against advances and to secure milestone performance. In section 14.5 it adds that guarantees outstanding stood at about NIS 118.3 million at December 31, 2025 and about NIS 115.9 million at the report date.
The key detail sits in section 14.4. The committed bank-guarantee line stood at NIS 76 million, of which NIS 75.5 million was used at year-end and NIS 73 million was used near the report date. At the same time, the company was using another NIS 42.8 million at year-end and NIS 42.9 million near the report date through unsecured and non-committed bank credit for ongoing funding needs and guarantees. In other words, the large guarantee stock sits in a setup where the committed line is already close to full and the company is also relying on a non-committed layer of bank support.
That is the core link between contract assets and guarantees. When the customer funds a larger share of the project, DSIT still needs to post guarantees, but cash arrives relatively early. When execution runs ahead of billing, the company not only carries the gap on its balance sheet, it also continues to carry a large guarantee stock in order to keep the projects moving. So the 2025 problem was not only that cash flow weakened. The problem was that growth started to consume guarantee capacity as well.
It is important to separate capacity pressure from covenant pressure. The company was comfortably in compliance at the end of 2025: tangible-equity ratio was 28.5% against a 16% floor, tangible equity was NIS 27.551 million against a NIS 10 million minimum, and the ratio of financial debt plus guarantees to tangible equity was 1.85 against a ceiling of 4. This is not a near-breach story. But that does not mean capacity is unlimited. It only means the next bottleneck is line availability, bank willingness, and capital quality, not an immediate covenant event.
What The IPO Did Buy, And What It Did Not
Note 26 changes the tone, rightly so. In March 2026 DSIT completed its IPO and raised NIS 52.031 million gross, or NIS 48.610 million net. In chapter D the company even states that by the report publication date no use had yet been made of the IPO proceeds. At the same time, the director report says that as of the report date the main funding sources were ongoing operations and IPO proceeds, and section 14.6 reports liquidity of about $21.4 million and no expected need for additional funding in the coming year.
So the IPO clearly bought time. It also strengthened the capital layer on which the banking tests rest. Net IPO proceeds of NIS 48.610 million were larger than the NIS 27.551 million of tangible equity on which the year-end covenant tests were based. That is a material improvement in balance-sheet breathing room.
But the IPO did not buy one thing: it did not turn company cash into bank guarantees automatically. Customers ask for guarantees, and banks provide them through credit lines and financing agreements. So the new money solves the immediate survival question and improves balance-sheet flexibility, but it does not remove the capacity question if execution again runs ahead of billing in 2026.
There is also an early live test already in the filing. In February 2026 the new European agreement was signed, and the initial roughly $9.7 million quantity includes an advance payment of about 30%, while an additional quantity of up to about $4 million is payable on delivery. That does not solve the whole issue, but it sharpens what the market should now look for: are new contracts bringing real customer funding back into the model, or are they merely adding more work that the company has to carry until delivery.
Conclusions
The continuation thesis here is simpler, and sharper, than in the main article: 2025 was the year in which DSIT's growth stopped being funded mainly by the customer and started leaning more heavily on the company's own balance sheet and banking capacity.
That does not mean the growth is not real. On the contrary, it is very real. Revenue increased, projects moved forward, and the company advanced into deeper execution phases. But that is exactly why 2025 showed that revenue is not the same as cash, and backlog is not automatically the same as balance-sheet freedom.
The strongest counter-thesis is that all of this is mainly timing. On that view, 2025 simply reflects a project phase in which invoices arrive later, and after the IPO there is no reason to treat the gap as structural. That is a serious argument, especially because the company is nowhere near a covenant problem, raised fresh money, and already has a new European contract with an advance-payment component.
But for now it remains only a counter-thesis, because the numbers still say one clear thing: in 2024 billings led revenue, in 2025 revenue led billings, and that gap hit both the cash balance and guarantee capacity directly. Until that trend reverses, the market should read DSIT not just as a growth company, but as a growth company funding more of its acceleration itself than it did before.
What would change that reading in the near term? Three signals. First, contract assets need to flatten or at least slow relative to revenue. Second, billing and collections need to accelerate so that execution is again supported by customer funding. Third, the company needs to maintain a large guarantee stock without continuing to sit almost entirely on the committed line. If those three signals appear together, 2025 will look like a transition period in hindsight. If not, it will be evidence that DSIT's next bottleneck is not demand, but execution funding.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.